161 results
Page 4 of 9
8-K
EX-99.1
pqjdp ufmt
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
9z6mut0mm9iy1lupy
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
gbp7 ilssshg
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
1uzg57cxd
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
4jlqemg4s 7f4w96e0
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
zpkthe
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
s2u64rk8n3qq68ctl1
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
EX-99.1
m540fq
18 May 21
Other Events
3:09pm
8-K
EX-99.1
hy3940x96gla3j
11 May 21
Other Events
8:34am
8-K
EX-99.2
tjofgi2rrjtcu
11 May 21
Other Events
8:34am
8-K
EX-99.1
7bxaji 69
10 May 21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:15pm
8-K/A
EX-99.1
owglrwmkkc ny
4 Mar 21
Unaudited Pro Forma Combined Financial Statements
5:16pm
8-K
EX-99.1
gu9r332u
4 Mar 21
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
7:30am
8-K
EX-99.2
otn8fc1
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
wim9rfc0cvehii0
8 Dec 20
Regulation FD Disclosure
7:40am
8-K/A
EX-99.1
vb36fvov5fr
12 Nov 20
Unaudited Pro Forma Combined Financial Statements
4:51pm